Bayesian estimation of cost-effectiveness ratios from clinical trials.

Estimation of the incremental cost-effectiveness ratio (ICER) is difficult for several reasons: treatments that decrease both cost and effectiveness and treatments that increase both cost and effectiveness can yield identical values of the ICER; the ICER is a discontinuous function of the mean difference in effectiveness; and the standard estimate of the ICER is a ratio. To address these difficulties, we have developed a Bayesian methodology that involves computing posterior probabilities for the four quadrants and separate interval estimates of ICER for the quadrants of interest. We compute these quantities by simulating draws from the posterior distribution of the cost and effectiveness parameters and tabulating the appropriate posterior probabilities and quantiles. We demonstrate the method by re-analysing three previously published clinical trials.

[1]  N. Blomqvist,et al.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. , 1998, Statistics in medicine.

[2]  Donald A. Berry.  Statistics : a Bayesian perspective : student solutions manual , 1996 .

[3]  M Meisner,et al.  Statistical inference for cost-effectiveness ratios. , 1997, Health economics.

[4]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[5]  S. Opal,et al.  Human neutrophil bactericidal/permeability‐increasing protein reduces mortality rate from endotoxin challenge: A placebo‐controlled study , 1994, Critical care medicine.

[6]  Bernie J. O'Brien,et al.  In Search of Power and Significance: Issues in the Design and Analysis of Stochastic Cost-Effectiveness Studies in Health Care , 1994, Medical care.

[7]  D. Heitjan,et al.  Fieller's method and net health benefits. , 2000, Health economics.

[8]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[9]  A A Stinnett,et al.  The negative side of cost-effectiveness analysis. , 1997, JAMA.

[10]  G. C. Tiao,et al.  Bayesian inference in statistical analysis , 1973 .

[11]  A J Moskowitz,et al.  Problems with Interval Estimates of the Incremental Cost—Effectiveness Ratio , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[13]  Donald A. Berry,et al.  Statistics: A Bayesian Perspective , 1995 .

[14]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[15]  D Polsky,et al.  Confidence intervals for cost-effectiveness ratios: a comparison of four methods. , 1997, Health economics.

[16]  A A Stinnett,et al.  Net Health Benefits , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.